Transforming the Future for Patients With Developmental and Epileptic Encephalopathies (DEEs)
At Praxis, we’re at the forefront of innovation, pioneering bold new science to reshape what’s possible for patients living with DEEs and related syndromes.
We are currently investigating 2 first-in-class therapies designed specifically to target the underlying biology of DEEs:
Relutrigine (PRAX-562): A novel precision approach with the potential to significantly reduce seizure burden.
Elsunersen (PRAX-222): An antisense oligonucleotide built to address the root genetic cause of early-onset SCN2A DEE.
Both investigational therapies aim to not only reduce seizures, but also to improve overall quality of life for patients and families navigating these complex syndromes.
Let’s advance care together
If you’re a healthcare professional passionate about bringing transformative therapies to patients with DEEs, we invite you to connect with our Praxis medical team to learn more about the Resilience Clinical Trial Program. Share your contact information, and a member of our team will reach out shortly to discuss how you can be part of this important work.
Together, we can redefine what’s possible for patients with DEEs.
